Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
Men's Health | Women's Health
What is the purpose of this trial?
This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).
- Ages50 years - 80 years
- Trial withAlzheimer's Association
- Start Date03/25/2021
- End Date06/01/2022
- Last Updated06/26/2022
- Study HIC#2000028864